Madrigal Pharmaceuticals Inc (MDGL) - Total Liabilities
Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) has total liabilities worth $656.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MDGL cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Madrigal Pharmaceuticals Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how Madrigal Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Madrigal Pharmaceuticals Inc asset portfolio.
Madrigal Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Madrigal Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VERBUND AG
VI:VER
|
Austria | €7.10 Billion |
|
Shanghai Electric Group Co Ltd
SHG:601727
|
China | CN¥239.40 Billion |
|
PayPay Corporation American Depository Shares
NASDAQ:PAYP
|
USA | $5.04 Trillion |
|
Penske Automotive Group Inc
NYSE:PAG
|
USA | $12.64 Billion |
|
Eiffage SA
PA:FGR
|
France | €32.63 Billion |
|
Aker ASA
OL:AKER
|
Norway | Nkr47.56 Billion |
|
Equity Lifestyle Properties Inc
NYSE:ELS
|
USA | $3.93 Billion |
|
Doosan Corp.
KO:000150
|
Korea | ₩21.45 Trillion |
Liability Composition Analysis (2001–2025)
This chart breaks down Madrigal Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Madrigal Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Madrigal Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Madrigal Pharmaceuticals Inc (2001–2025)
The table below shows the annual total liabilities of Madrigal Pharmaceuticals Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $656.90 Million | +128.20% |
| 2024-12-31 | $287.86 Million | +22.38% |
| 2023-12-31 | $235.21 Million | +42.40% |
| 2022-12-31 | $165.18 Million | +113.90% |
| 2021-12-31 | $77.22 Million | +64.22% |
| 2020-12-31 | $47.02 Million | +84.48% |
| 2019-12-31 | $25.49 Million | +201.88% |
| 2018-12-31 | $8.44 Million | -16.01% |
| 2017-12-31 | $10.05 Million | +109.46% |
| 2016-12-31 | $4.80 Million | -73.02% |
| 2015-12-31 | $17.79 Million | -49.95% |
| 2014-12-31 | $35.54 Million | -22.93% |
| 2013-12-31 | $46.11 Million | +64.97% |
| 2012-12-31 | $27.95 Million | +1.46% |
| 2011-12-31 | $27.55 Million | -9.93% |
| 2010-12-31 | $30.59 Million | +27.46% |
| 2009-12-31 | $24.00 Million | -84.62% |
| 2008-12-31 | $156.04 Million | +59.63% |
| 2007-12-31 | $97.75 Million | +72.90% |
| 2006-12-31 | $56.54 Million | +201.80% |
| 2005-12-31 | $18.73 Million | +33.21% |
| 2004-12-31 | $14.06 Million | +302.26% |
| 2003-12-31 | $3.50 Million | +11955.17% |
| 2001-12-31 | $29.00K | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.